Abstract 5000: MYTX-011: A novel cMET-targeting antibody drug conjugate (ADC) engineered to increase on-target uptake in and efficacy against cMET expressing tumors
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-5000
Abstract: MET alterations can act as an oncogenic driver in non-small cell lung cancer (NSCLC) and elevated cMET expression occurs in many cancers. Antibody drug conjugates targeting cMET (cMET-ADCs) have been developed as a strategy to… read more here.
Keywords: cmet; adc; mytx 011; efficacy ... See more keywords
MYTX-011 in patients with previously treated locally advanced or metastatic NSCLC: Initial dose escalation results in the phase 1 KisMET-01 study.
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2024.42.16_suppl.8558
Abstract: 8558 Background: MYTX-011 is a novel cMET-targeted vcMMAE antibody-drug conjugate with a humanized monoclonal antibody that has been engineered to have pH-dependent binding, which results in higher internalization and payload delivery to tumor cells with… read more here.
Keywords: mytx 011; dose escalation; histology; tumor ... See more keywords